Clinical Trials · NCT02229396
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 695
- Start date
- Sep 2014
- Locations
- 133 sites, 6 countries
- Primary endpoint
- Change in HbA1c From Baseline to Week 28